{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T17:51:43Z","timestamp":1718128303709},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"award":["110402"],"award-info":[{"award-number":["110402"]}]},{"name":"Innovatie door Wetenschap en Technologie"},{"name":"Dafra Pharma International"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1093\/jac\/dkw089","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:43:17Z","timestamp":1460767397000},"page":"1892-1898","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis"],"prefix":"10.1093","volume":"71","author":[{"given":"Anny","family":"Fortin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P. C.","family":"Dorlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"2016060709374339000_71.7.1892.1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035671"},{"key":"2016060709374339000_71.7.1892.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00347-X"},{"key":"2016060709374339000_71.7.1892.3","unstructured":"WHO. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22\u201326 March 2010. WHO Technical Report Series 949. http:\/\/apps.who.int\/iris\/bitstream\/10665\/44412\/1\/WHO_TRS_949_eng.pdf ."},{"key":"2016060709374339000_71.7.1892.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70011-6"},{"key":"2016060709374339000_71.7.1892.5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks273"},{"key":"2016060709374339000_71.7.1892.6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003144"},{"key":"2016060709374339000_71.7.1892.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-013-3638-2"},{"key":"2016060709374339000_71.7.1892.8","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1038\/srep04156","article-title":"Drug delivery by tattooing to treat cutaneous leishmaniasis","volume":"4","author":"Shio","year":"2014","journal-title":"Sci Rep"},{"key":"2016060709374339000_71.7.1892.9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.18433\/J3CW23","article-title":"Alkylphospholipids\u2014a promising class of chemotherapeutic agents with a broad pharmacological spectrum","volume":"16","author":"Pachioni Jde","year":"2013","journal-title":"J Pharm Pharm Sci"},{"key":"2016060709374339000_71.7.1892.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.130-136.2004"},{"key":"2016060709374339000_71.7.1892.11","doi-asserted-by":"crossref","unstructured":"Maes L , Cos P , Croft S . The relevance of susceptibility tests, breakpoints and markers. In: Ponte-Sucre A , Diaz E , Padr\u00f3n-Nieve M , eds. Drug Resistance in Leishmania Parasites . London: Springer, 2013; 407\u201329.","DOI":"10.1007\/978-3-7091-1125-3_19"},{"key":"2016060709374339000_71.7.1892.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.11.008"},{"key":"2016060709374339000_71.7.1892.13","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-007-3026-8"},{"key":"2016060709374339000_71.7.1892.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.02.010"},{"key":"2016060709374339000_71.7.1892.15","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9574LSF"},{"key":"2016060709374339000_71.7.1892.16","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther Clin Risk Manag"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/71\/7\/1892\/11282829\/dkw089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T19:22:19Z","timestamp":1567797739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,6,7]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1093\/jac\/dkw089"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw089","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]}}}